CJC-1295 is one of the most referenced growth-hormone-releasing peptides in the research literature, and one of the most frequently confused. Part of that confusion comes from two closely related versions of the molecule that get used interchangeably online but behave very differently. This overview walks through what CJC-1295 actually is, how it's understood to work, the DAC-versus-no-DAC distinction that trips people up, and how to evaluate a research-grade preparation.

This article is for educational and research reference only. It is not medical advice, and Element materials are sold for laboratory and research use.

What CJC-1295 is

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). The body's own GHRH is a signaling peptide released by the hypothalamus that tells the pituitary gland to secrete growth hormone. It's a short-lived molecule by design — it acts in pulses and is broken down quickly.

CJC-1295 is built on the first 29 amino acids of GHRH — the fragment that carries the biological activity — with targeted amino-acid substitutions that protect it from the enzymes that normally degrade natural GHRH. The result is a GHRH-like molecule that resists breakdown far longer than the native hormone. That stability is the entire point of the modification, and it's the property most of the research interest is built on.

The DAC vs no-DAC distinction

This is the single most important thing to understand, because the two forms are often sold under the same "CJC-1295" name:

  • CJC-1295 with DAC carries a Drug Affinity Complex — a chemical group that lets the peptide bind reversibly to albumin, a protein that circulates in blood. Tethered to albumin, the molecule persists far longer, which in research settings translates to a substantially extended half-life measured in days rather than minutes.
  • CJC-1295 without DAC — more accurately called modified GRF (1-29) or "mod GRF 1-29" — keeps the stabilizing substitutions but omits the albumin-binding complex. It's still far more durable than natural GHRH, but its action is shorter and more pulse-like, closer to how endogenous GHRH behaves.

The distinction matters because the two forms produce different pharmacological profiles in study models: DAC creates a sustained elevation, while no-DAC produces a sharper, more transient signal. Researchers choose between them based on which profile a given experiment calls for. When you see "CJC-1295," always confirm which version a supplier is actually shipping — the certificate of analysis should specify it.

How it's understood to work

CJC-1295 acts on the GHRH receptor on pituitary cells. By mimicking GHRH but resisting degradation, it prolongs the signal that prompts the pituitary to release growth hormone. Downstream of growth hormone, the liver produces IGF-1 (insulin-like growth factor 1), the mediator through which many of GH's effects are studied.

A key concept in the research framing is that CJC-1295 works upstream, at the level of the body's own release machinery, rather than introducing growth hormone directly. In study models this preserves the pituitary's natural pulsatile pattern of secretion — one of the reasons GHRH analogs are of interest to researchers studying the GH axis as a system rather than just flooding it with exogenous hormone.

Why it's often paired with a GHRP in research

In the literature, GHRH analogs like CJC-1295 are frequently studied alongside a second class of peptides — growth-hormone-releasing peptides (GHRPs) such as ipamorelin. The rationale is mechanistic: GHRH analogs and GHRPs act on two different receptors and two different pathways that both converge on growth hormone release. Studied together, they've been reported to produce a combined effect greater than either alone, because they're pulling two separate levers on the same system.

This pairing is a recurring theme in GH-axis research, which is why the two peptides are so often discussed in the same breath. It's a mechanistic observation from study models, not a usage recommendation.

What the research has examined

Most of the relevant work sits in a few areas:

  • GH and IGF-1 dynamics. The core body of research looks at how GHRH analogs affect growth hormone secretion patterns and downstream IGF-1 levels in animal and clinical pharmacology models.
  • Half-life and pharmacokinetics. A significant share of the CJC-1295 literature is specifically about the DAC modification and how albumin binding extends the molecule's duration — the foundational work that made the peptide notable in the first place.
  • The GH axis as a regulatory system. Because CJC-1295 acts upstream, it's used as a tool for studying how the hypothalamic-pituitary axis regulates growth hormone, rather than only its end effects.

As always, the honest framing is that this is characterized pharmacology in research contexts. Claims that leap from "affects GH secretion in a study model" to specific real-world outcomes run ahead of what the data support.

Stability, storage, and handling

For a research-grade lyophilized peptide, standard handling principles apply:

  • Store the sealed, freeze-dried powder cold and away from light. Lyophilized peptide is dramatically more stable than peptide in solution.
  • Once in solution, refrigerate and treat stability as a matter of weeks, not months.
  • Avoid repeated freeze-thaw cycles, which degrade peptides.
  • Use appropriate diluents. Research handling typically uses bacteriostatic water as the diluent because its preservative supports a longer usable window than sterile water once a vial is opened.
  • Label and date solutions so batches don't get mixed up.

These are storage and stability considerations for lab material — not a use protocol.

How to evaluate quality

CJC-1295 is a peptide where quality varies wildly between suppliers, so this is where your attention pays off:

  • Which version is it? The COA should state clearly whether it's CJC-1295 with DAC or without DAC (mod GRF 1-29). If a listing doesn't specify, that's a red flag.
  • Third-party COA. A legitimate supplier provides a Certificate of Analysis from an independent lab, batch-specific, not an in-house claim.
  • Purity by HPLC, with a stated figure (commonly ≥98%).
  • Identity by mass spectrometry, confirming the correct molecular weight for the specific version.

If a supplier can't produce a current, batch-matched COA that names the DAC status, treat the product as unverified.

Frequently asked questions

What's the difference between CJC-1295 and mod GRF 1-29? "Mod GRF 1-29" is CJC-1295 without the DAC complex. Both are stabilized GHRH analogs; the DAC version lasts far longer by binding to albumin, while the no-DAC version acts in a shorter, more pulse-like way.

Why is CJC-1295 studied with ipamorelin? They act on different receptors that both lead to growth hormone release, so in research models the combination produces a larger effect than either peptide on its own.

Does CJC-1295 contain growth hormone? No. It's a GHRH analog that acts on the body's own pituitary release machinery — it works upstream, not by adding growth hormone directly.

What should I check before buying? A current, third-party COA that names the version (DAC vs no-DAC) and reports HPLC purity and mass-spec identity for the specific batch.

Element supplies research-grade materials for laboratory use. Nothing here is medical advice or a recommendation for human use. Browse related research peptides for compounds studied in the same context.